Clover in Phase 3 Trial of COVID-19 Booster After Inactivated, mRNA or Viral Vector Vaccines

 

• Study to evaluate SCB-2019 (CpG 1018/Alum) as a heterologous booster in individuals previously vaccinated with CoronaVac™ (Sinovac Inactivated Vaccine), Comirnaty^® (Pfizer mRNA Vaccine), and Vaxzevria^® (AstraZeneca Viral Vector Vaccine)
• Safety & immunogenicity data expected for key 3^rd dose booster groups (CoronaVac™ and Comirnaty^®) in Q3-2022 and the 4^th dose booster group (CoronaVac™) in Q4-2022
• Study to expand dataset supporting the potential use of SCB-2019 (CpG 1018/Alum) as a universal COVID-19 booster vaccine

https://www.biospace.com/article/releases/clover-doses-first-participants-in-phase-3-trial-evaluating-scb-2019-as-a-heterologous-covid-19-booster-following-prior-vaccination-with-inactivated-mrna-or-viral-vector-vaccines/